20-valent Pneumococcal Polysaccharide Conjugate Vaccine

The 20-valent Pneumococcal Polysaccharide Conjugate Vaccine is a pharmaceutical vaccine designed to protect against diseases caused by 20 specific serotypes of *Streptococcus pneumoniae*. It is a conjugate vaccine, meaning it combines purified capsular polysaccharides from these 20 serotypes with a carrier protein. This conjugation enhances the immune response by converting a T-cell independent response into a T-cell dependent response, leading to a more robust and long-lasting immunity, including the generation of memory B cells. This specific 20-valent vaccine is currently undergoing clinical trials by Beijing Minhai Biotechnology Co., Ltd and Hubei Provincial Center for Disease Control and Prevention for the prevention of pneumococcal disease.